A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of TP-04 in Participants With Papulopustular Rosacea
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Lotilaner (Primary)
- Indications Rosacea
- Focus Adverse reactions
- Acronyms Galatea
- Sponsors Tarsus Pharmaceuticals
Most Recent Events
- 01 Mar 2024 Positive topline results discussing Statistically significant improvements (p<0.05) in inflammatory lesions and Investigators Global Assessment (IGA) score ,were published in Tarsus Pharmaceuticals media release.
- 27 Feb 2024 Results published in the Media Release
- 22 Nov 2023 Status changed from active, no longer recruiting to completed.